Eyegenex

Based in the US, Eyegenex, operates as a company that offers eye disease therapies. Based in La Jolla, the US and founded in 2023, Eyegenex develops therapies for eye diseases. The company focuses on neuroprotective therapies targeting conditions such as non-arteritic anterior ischemic optic neuropathy and glaucoma. In September 2026, Eyegenex raised USD 0.

745 mn in Unspecified Round funding from Newsight Tech Angels and NuFund Venture Group to accelerate its preclinical work and regulatory engagement toward first-in-human testing. Eyegenex primarily focuses on developing neuroprotective therapies that harness small heat shock protein biology to protect retinal ganglion cells, specifically targeting non-arteritic anterior ischemic optic neuropathy (NAION), glaucoma, and other optic neuropathies. The company’s lead product, EGX-009, is a synthetic peptide designed to intervene shortly after acute optic nerve injuries, preserving retinal ganglion cell viability and maintaining neuronal signaling to the brain. The company plans to advance EGX-009 into a Phase 1b/2a clinical study, with additional products, such as EGX-001 and EGX-018, also being developed for related indications.

Eyegenex's revenue model is structured around the advancement of its investigational therapies, principally EGX-009, through clinical development to eventual commercialization. The company may engage in B2B transactions, collaborating with pharmaceutical companies or research institutions for further development and regulatory approval. Partnerships may also be established for distribution and marketing once the products receive necessary approvals. The revenue framework will likely evolve as Eyegenex transitions from preclinical research to FDA-approved therapeutics for acute and chronic ocular conditions.

The company plans to use the recent funding to accelerate completion of its preclinical work and regulatory engagement toward first-in-human testing.